azidocmp sialic acid (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
90
Structured Review
R&D Systems
azidocmp sialic acid
Azidocmp Sialic Acid, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/azidocmp+sialic+acid/CMP-Azido-Sialic+Acid/pm31381874-48-52-54
Average 90 stars, based on 2 article reviews
Azidocmp Sialic Acid, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/azidocmp+sialic+acid/CMP-Azido-Sialic+Acid/pm31381874-48-52-54
Average 90 stars, based on 2 article reviews
azidocmp sialic acid - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Produced:Article Title: Chemoenzymatic glycan labelling as a platform for site-specific IgM-antibody drug conjugates. Article Snippet: Immunoglobulin M (IgM) type antibodies play a significant role in complement activation, cellular debris clearance and cell quality control, and have the potential to be used as a therapeutic or targeting/delivery antibody.. However, this potential has not been explored thoroughly due to its high molecular weight, polymeric structure and large number of glycosylation sites.. Site-specific antibody-drug-conjugates (ADC) are considered the next generation protein biotherapeutic drugs and currently all, in clinical trials and approved, are of the IgG isotype. Recombinant:Article Title: Chemoenzymatic glycan labelling as a platform for site-specific IgM-antibody drug conjugates. Article Snippet: Immunoglobulin M (IgM) type antibodies play a significant role in complement activation, cellular debris clearance and cell quality control, and have the potential to be used as a therapeutic or targeting/delivery antibody.. However, this potential has not been explored thoroughly due to its high molecular weight, polymeric structure and large number of glycosylation sites.. Site-specific antibody-drug-conjugates (ADC) are considered the next generation protein biotherapeutic drugs and currently all, in clinical trials and approved, are of the IgG isotype. Incubation:Article Title: Chemoenzymatic glycan labelling as a platform for site-specific IgM-antibody drug conjugates. Article Snippet: Immunoglobulin M (IgM) type antibodies play a significant role in complement activation, cellular debris clearance and cell quality control, and have the potential to be used as a therapeutic or targeting/delivery antibody.. However, this potential has not been explored thoroughly due to its high molecular weight, polymeric structure and large number of glycosylation sites.. Site-specific antibody-drug-conjugates (ADC) are considered the next generation protein biotherapeutic drugs and currently all, in clinical trials and approved, are of the IgG isotype. |